Warren Huff, Reata Pharmaceuticals CEO
Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
Reata’s long and winding road with bardoxolone appears to be over.
The Plano, TX-based biotech and partner Kyowa Kirin said Wednesday morning that they are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
